The slow death of the medtech Spac deal
The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.
Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
Takeout premiums hold up, but that’s not the whole story
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
Nektar and Puretech make strange bedfellows
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
No big bang for biopharma buyouts
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.
The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
For medtechs seeking deals, it’s hurry up and wait
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.